Drugs / Umeta-Miyue
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03894813 | Mar 2019 → Dec 2020 | bacterial vaginosis | Peking University Shenzhen Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umeta-Miyue | “Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)” NCT03894813 ↗ |
| Modality | Other / unclassified | “Oral probiotics” NCT03894813 ↗ |
| Route | Oral | “Oral probiotics” NCT03894813 ↗ |